Premium
Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No
Author(s) -
KHAMASHTA M. A.,
HUNT B. J.
Publication year - 2005
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/j.1538-7836.2005.01405.x
Subject(s) - medicine , antiphospholipid syndrome , thrombosis , venous thrombosis , pregnancy , retrospective cohort study , prospective cohort study , stroke (engine) , cardiology , surgery , mechanical engineering , genetics , engineering , biology
See also Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, Baudo F, Berrettini M, Testa S, D’Angelo A, Tognoni G, Barbui T. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). This issue, pp 848–53; Anderson DR. Oral anticoagulation for the antiphospholipid antibody syndrome: can we now say less is more? This issue, pp 846–7; Rickles FR, Marder VJ. Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No. This issue, pp 842–3; Scully M-F. Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? Yes, This issue, pp 840–1.